Status:
ACTIVE_NOT_RECRUITING
PICAROS - Acalabrutinib RWE on 1L CLL in Spain
Lead Sponsor:
AstraZeneca
Conditions:
Chronic Lymphocytic Leukemia
Eligibility:
All Genders
18+ years
Brief Summary
This is a multicenter non-interventional study (NIS) on patients with CLL who have been treated with acalabrutinib for the first time within the year before the first site initiation visit in Spain
Detailed Description
This is a multicenter, non-interventional study (NIS) based on ambispective (including retrospective and/or prospective) real-world data collection of patients with CLL who have been treated with acal...
Eligibility Criteria
Inclusion
- Age ≥18 years old at starting acalabrutinib treatment.
- Diagnosis of CLL.
- Start of acalabrutinib treatment (index date) in treatment-naïve CLL patients or those switching in first-line between first-generation BTK inhibitor to acalabrutinib due to intolerance in absence of progression according to routine clinical practice within the year before the first site initiation visit. Decision to administer acalabrutinib must be made and documented prior to inclusion into the study and must follow local clinical practice.
- Informed consent (for alive patients).
Exclusion
- Enrolled in any clinical trial during acalabrutinib treatment.
- Patients who are unable to understand the study and its questionnaires due to insufficient knowledge of the Spanish language or their health status.
Key Trial Info
Start Date :
July 11 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2026
Estimated Enrollment :
192 Patients enrolled
Trial Details
Trial ID
NCT05999877
Start Date
July 11 2023
End Date
December 31 2026
Last Update
December 29 2025
Active Locations (47)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Almería, Andalusia, Spain, 4009
2
Research Site
Córdoba, Andalusia, Spain, 14004
3
Research Site
Granada, Andalusia, Spain, 18014
4
Research Site
Jaén, Andalusia, Spain, 23007